J&J takes an­oth­er big step for­ward with next-gen prostate can­cer block­buster apa­lu­tamide

J&J needs a big win from its phar­ma R&D group. And now it’s tak­ing its shot.

Over the last year, J&J and Pfiz­er have been bat­tling it out to ex­pand the mar­ket for their ri­val prostate can­cer drugs Zyti­ga and Xtan­di, of­fer­ing da­ta that could ex­pand their reach in­to new pa­tient groups. But J&J has now tak­en an even big­ger move: fil­ing for an ap­proval of apa­lu­tamide with the FDA for non-metasta­t­ic, cas­tra­tion-re­sis­tant prostate can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER